This Article Full Text Full Text (PDF) All Versions of this Article: 105/20/2347    most recent 01.CIR.0000017635.82128.8Cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, G. W. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Stone, G. W. Articles by Topol, E. J. Related Collections Acute coronary syndromes Platelet function inhibitors Catheter-based coronary interventions: stents

(Circulation. 2002;105:2347.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting

The TARGET Trial^*

Gregg W. Stone, MD; David J. Moliterno, MD; Michel Bertrand, MD; Franz-Josef Neumann, MD; Howard C. Herrmann, MD; Eric R. Powers, MD; Cindy L. Grines, MD; Jeffrey W. Moses, MD; David J. Cohen, MD; Eric A. Cohen, MD; Marc Cohen, MD; Kathy Wolski, MS; Peter M. DiBattiste, MD; Eric J. Topol, MD

From the Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY.

Correspondence to Gregg W. Stone, MD, The Cardiovascular Research Foundation, 55 E 59th St, 6th Floor, New York City, NY 10022. E-mail gstone{at}crf.org

Background— Although glycoprotein IIb/IIIa inhibitors have been shown to reduce periprocedural and late ischemic events in patients undergoing stent implantation, the relative safety and efficacy of different agents in this class is less established. Also unknown is whether the acuity of the presenting clinical syndrome, which may affect the degree of platelet inhibition required or achieved, influences the response to different antiplatelet agents.

Methods and Results— A prospective, multicenter, double-blind, randomized trial was performed in which 4809 patients undergoing planned stenting were randomized to receive abciximab or tirofiban. In patients with acute coronary syndromes (ACS; n=3025), abciximab resulted in lower rates of myocardial infarction at 30 days (5.8% versus 8.5%; P=0.004) and 6 months (7.2% versus 9.8%; P=0.013), although 6-month mortality rates were identical (1.39% in both groups; P=0.99). Conversely, in patients without ACS (n=1784), myocardial infarction rates were not significantly lower with tirofiban, survival was similar, and target vessel revascularization was reduced, which translated into a trend toward enhanced 6-month event-free survival with tirofiban (89.7% versus 86.6%; P=0.056).

Conclusions— In patients with ACS undergoing stent implantation, abciximab use compared with tirofiban results in greater suppression of periprocedural myonecrosis, although a survival benefit has not been demonstrated. Patients with stable coronary syndromes may have equivalent or better outcomes with tirofiban relative to abciximab, with fewer adverse hematologic and hemorrhagic events. These data raise important issues regarding the relative pharmacodynamic inhibition of platelet function required in varying clinical scenarios and have important implications for the cost-effective utilization of glycoprotein IIb/IIIa inhibitors.

Key Words: angioplasty • stents • platelets

This article has been cited by other articles:

				W. Hochholzer, D. Trenk, H.-P. Bestehorn, B. Fischer, C. M. Valina, M. Ferenc, M. Gick, A. Caputo, H. J. Buttner, and F.-J. Neumann Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1742 - 1750. [Abstract] [Full Text] [PDF]

				Additional Information JAMA, March 15, 2006; 295(11): E7 - E14. [Full Text] [PDF]

				R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537. [Abstract] [Full Text] [PDF]

				D. Mukherjee, E. J. Topol, M. E. Bertrand, S. D. Kristensen, H. C. Herrmann, F.-J. Neumann, S. J. Yakubov, J.-P. Bassand, R. R. McClure, G. W. Stone, et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up Eur. Heart J., December 1, 2005; 26(23): 2524 - 2528. [Abstract] [Full Text] [PDF]

				J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]

				J. W. Moses, R. Mehran, E. Nikolsky, J. M. Lasala, W. Corey, G. Albin, C. Hirsch, M. B. Leon, M. E. Russell, S. G. Ellis, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: Analysis from the TAXUS-IV trial J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1165 - 1171. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]

				M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial J. Am. Coll. Cardiol., July 7, 2004; 44(1): 14 - 19. [Abstract] [Full Text] [PDF]

				A. W. Chan, D. J. Moliterno, P. B. Berger, G. W. Stone, P. M. DiBattiste, S. L. Yakubov, S. K. Sapp, K. Wolski, D. L. Bhatt, E. J. Topol, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival: Results from the do tirofiban and reoprogive similar efficacy outcome trial (TARGET) J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1188 - 1195. [Abstract] [Full Text] [PDF]

				F.-J. Neumann, A. Kastrati, G. Pogatsa-Murray, J. Mehilli, H. Bollwein, H.-P. Bestehorn, C. Schmitt, M. Seyfarth, J. Dirschinger, and A. Schomig Evaluation of Prolonged Antithrombotic Pretreatment ("Cooling-Off" Strategy) Before Intervention in Patients With Unstable Coronary Syndromes: A Randomized Controlled Trial JAMA, September 24, 2003; 290(12): 1593 - 1599. [Abstract] [Full Text] [PDF]

				M. J. Ross, H. C. Herrmann, D. J. Moliterno, J. C. Blankenship, L. Demopoulos, P. M. DiBattiste, S. G. Ellis, Z. Ghazzal, J. L. Martin, J. White, et al. Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition: Results from the TARGET trial J. Am. Coll. Cardiol., September 17, 2003; 42(6): 981 - 988. [Abstract] [Full Text] [PDF]

				Abciximab vs. Tirofiban in ACS vs. Non-ACS Patients Journal Watch Cardiology, July 19, 2002; 2002(719): 2 - 2. [Full Text]